Conclusion: CK 56 expression breast carcinoma implies a 'basal like' molecular phenotype and is associated with poor prognosis. This antibody is also used as a component of panels to differentiate benign and malignant breast lesions. Keywords: Benign and malignant breast lesions, cytokeratin 56, immunohistochemistry